Alector to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Alector (Nasdaq: ALEC), a clinical-stage biotechnology company specializing in immuno-neurology, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference. The event is scheduled for Monday, June 10, 2024, at 1:20 p.m. ET. A live webcast will be accessible via the Investors section of Alector's website, with a replay available for 90 days post-event.
- Alector's participation in the Goldman Sachs 45th Annual Global Healthcare Conference highlights its growing recognition in the healthcare industry.
- The event provides Alector with a platform to showcase its advancements and strategies to potential investors and stakeholders.
- The availability of a live webcast and a 90-day replay increases transparency and accessibility for investors.
- The press release lacks concrete financial or clinical data updates that could directly impact investor decisions.
- There is no mention of any new product developments, partnerships, or milestones achieved.
- The information provided is to an event announcement, which may not significantly influence stock performance.
SOUTH SAN FRANCISCO, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024, at 1:20 p.m. ET.
A live webcast of the fireside chat will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com. A replay will be available on the Alector website for 90 days following the event.
About Alector
Alector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered and is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable rejuvenated immune cells to counteract emerging brain pathologies. Alector’s immuno-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimer’s disease and genetically defined frontotemporal dementia patient populations. Alector is headquartered in South San Francisco, California.
Alector Contacts:
Alector
Katie Hogan
202-549-0557
katie.hogan@alector.com
1AB (media)
Dan Budwick
973-271-6085
dan@1abmedia.com
Argot Partners (investors)
Laura Perry
212.600.1902
alector@argotpartners.com
FAQ
What event will Alector participate in on June 10, 2024?
How can I watch Alector's presentation at the Goldman Sachs Healthcare Conference?
Will there be a replay available for Alector's presentation at the Goldman Sachs Healthcare Conference?
What time is Alector's fireside chat at the Goldman Sachs Conference?
What is the stock symbol for Alector?
